Bipolar Disorder

Psychiatry experts explain why off-label psych meds and polypharmacy can be essential.

New evidence shows lithium adds minimal weight in bipolar disorder and explains why some gain occurs—plus practical tips to prevent it.

Phase 2 study tests AL001 brain-targeted lithium in bipolar I, aiming to cut toxicity and monitoring via advanced MRI/MRS imaging.

A care partner shares how routines, early warning signs, supportive clinicians, and community help families manage bipolar I disorder and sustain hope.

New evidence suggests age-adjusted eGFR cutoffs refine CKD risk, guiding safer lithium use and avoiding unnecessary kidney alarms.

FDA clears Bysanti, a novel atypical antipsychotic for acute bipolar I and schizophrenia, leveraging Fanapt data; US launch planned 2026.

Adjunctive lithium sharply reduces relapse and suicidal ideation, and attempts in patients with bipolar disorder and major depressive disorder.

Explore insights on bipolar disorder, including suicide risk assessment and comorbidities. Share your insights and experiences today with our February theme!

LB Pharmaceuticals initiates a phase 2 trial for LB-102, a promising treatment for bipolar depression, aiming to address unmet needs in mood disorders.

BioXcel Therapeutics submits an sNDA to the FDA for Igalmi to treat agitation in bipolar disorder and schizophrenia at home.

Clinicians can guide patients with bipolar disorder in setting flexible, achievable New Year’s goals, enhancing motivation and stability throughout mood fluctuations.

Syremis Therapeutics advances innovative drugs ST-905 and ST-901 for schizophrenia and major depressive disorder, aiming to transform mental health treatment.

Valproate's role in treating bipolar disorder is questioned as evidence suggests better alternatives exist for managing acute mania and maintenance.

New research suggests semaglutide may protect against lithium-induced renal injury, offering hope for safer bipolar disorder treatments.

In this CME article, explore effective strategies for assessing and preventing suicide risk in patients with bipolar disorder, including interdisciplinary approaches and evidence-based interventions.

Explore the evolving role of lamotrigine in treating bipolar depression, highlighting its benefits, risks, and recent clinical guidelines.

Laguna Diagnostics revolutionizes psychiatric interventions with patented blood tests that accurately diagnose schizophrenia and bipolar disorder.

Uzedy, a once-monthly extended release long-acting injectable, is now FDA approved for bipolar I disorder.

Explore the complexities of aripiprazole in bipolar disorder treatment, including its efficacy and proper prescribing practices.

In clinical practice, there are individuals who have chronic low-grade hypomanic symptoms: high energy, need for less sleep than others, chronic optimism, and chronic risk-taking.

FDA approves Amneal Pharmaceuticals' new long-acting injectable risperidone for schizophrenia, enhancing treatment options and potentially patient adherence.

NRX-100, a preservative-free ketamine, is granted expanded access for treatment of suicidal ideation in depression, offering new hope for patients.

BioXcel Therapeutics reveals promising phase 3 results from the SERENITY trial, paving the way for potential at-home treatment of agitation in bipolar disorder and schizophrenia.

BioXcel Therapeutics advances BXCL501 for at-home treatment of agitation in bipolar disorders and schizophrenia, aiming for FDA approval by 2026.